A Framework for Methodological Choice and Evidence Assessment for Studies Using External Comparators from Real-World Data

[1]  A. Abernethy,et al.  An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non–Small-Cell Lung Cancer , 2019, JCO clinical cancer informatics.

[2]  Haitao Chu,et al.  Effect estimates in randomized trials and observational studies: comparing apples with apples. , 2019, American journal of epidemiology.

[3]  Richard A. Nielsen,et al.  Why Propensity Scores Should Not Be Used for Matching , 2019, Political Analysis.

[4]  L. Hemkens.  How Routinely Collected Data for Randomized Trials Provide Long-term Randomized Real-World Evidence. , 2018, JAMA network open.

[5]  M. Posch,et al.  Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: methodological uncertainties , 2018, Orphanet Journal of Rare Diseases.

[6]  J. Ioannidis,et al.  Routinely collected data for randomized trials: promises, barriers, and implications , 2018, Trials.

[7]  Yvette van Norden,et al.  Including historical data in the analysis of clinical trials: Is it worth the effort? , 2017, Statistical methods in medical research.

[8]  J. Gagne,et al.  Synergies From Integrating Randomized Controlled Trials and Real‐World Data Analyses , 2017, Clinical pharmacology and therapeutics.

[9]  Tyler J. VanderWeele,et al.  Sensitivity Analysis in Observational Research: Introducing the E-Value , 2017, Annals of Internal Medicine.

[10]  Haolun Shi,et al.  Bayesian randomized clinical trials: From fixed to adaptive design. , 2017, Contemporary clinical trials.

[11]  A. Koch,et al.  A plea to provide best evidence in trials under sample-size restrictions: the example of pioglitazone to resolve leukoplakia and erythroplakia in Fanconi anemia patients , 2017, Orphanet Journal of Rare Diseases.

[12]  T. Lash,et al.  On the Need for Quantitative Bias Analysis in the Peer-Review Process , 2017, American journal of epidemiology.

[13]  E. Bertini,et al.  Neutral Lipid Storage Diseases: clinical/genetic features and natural history in a large cohort of Italian patients , 2017, Orphanet Journal of Rare Diseases.

[14]  A. Breckenridge,et al.  FDA Facilitated Regulatory Pathways: Visualizing Their Characteristics, Development, and Authorization Timelines , 2017, Front. Pharmacol..

[15]  D. Sargent,et al.  Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  C. Janson,et al.  Evaluation of the use of Swedish integrated electronic health records and register health care data as support clinical trials in severe asthma: the PACEHR study , 2016, Respiratory Research.

[17]  Su Golder,et al.  Reporting of Adverse Events in Published and Unpublished Studies of Health Care Interventions: A Systematic Review , 2016, PLoS medicine.

[18]  Timothy L Lash,et al.  Quantitative Bias Analysis in Regulatory Settings. , 2016, American journal of public health.

[19]  Gianluca Baio,et al.  Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999–2014 , 2016, BMJ Open.

[20]  James M Robins,et al.  Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. , 2016, American journal of epidemiology.

[21]  Sebastien Haneuse,et al.  Learning About Missing Data Mechanisms in Electronic Health Records-based Research: A Survey-based Approach , 2016, Epidemiology.

[22]  W Goettsch,et al.  From adaptive licensing to adaptive pathways: Delivering a flexible life‐span approach to bring new drugs to patients , 2015, Clinical pharmacology and therapeutics.

[23]  Andrea Manca,et al.  NICE DSU TECHNICAL SUPPORT DOCUMENT 17: THE USE OF OBSERVATIONAL DATA TO INFORM ESTIMATES OF TREATMENT EFFECTIVENESS IN TECHNOLOGY APPRAISAL: METHODS FOR COMPARATIVE INDIVIDUAL PATIENT DATA , 2015 .

[24]  Richard F MacLehose,et al.  Good practices for quantitative bias analysis. , 2014, International journal of epidemiology.

[25]  Anthony O'Hagan,et al.  Robust meta‐analytic‐predictive priors in clinical trials with historical control information , 2014, Biometrics.

[26]  D. Schriger,et al.  Looking through the retrospectoscope: reducing bias in emergency medicine chart review studies. , 2014, Annals of emergency medicine.

[27]  J. Crowley,et al.  Historical controls for metastatic pancreatic cancer: benchmarks for planning and analyzing single-arm phase II trials. , 2014, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  B. Carlin,et al.  Semiparametric Bayesian commensurate survival model for post‐market medical device surveillance with non‐exchangeable historical data , 2014, Biometrics.

[29]  I. White,et al.  A toolkit for measurement error correction, with a focus on nutritional epidemiology , 2014, Statistics in medicine.

[30]  Fang Chen,et al.  Use of historical control data for assessing treatment effects in clinical trials , 2014, Pharmaceutical statistics.

[31]  L. Kux.  OF HEALTH AND HUMAN SERVICES Food and Drug Administration , 2014 .

[32]  D Kalra,et al.  Electronic health records: new opportunities for clinical research , 2013, Journal of internal medicine.

[33]  Brian P Hobbs,et al.  Adaptive adjustment of the randomization ratio using historical control data , 2013, Clinical trials.

[34]  Sander Greenland,et al.  Adjusting for outcome misclassification: the importance of accounting for case-control sampling and other forms of outcome-related selection. , 2013, Annals of epidemiology.

[35]  Michael G. Kenward,et al.  Multiple Imputation and its Application , 2013 .

[36]  Michael G. Kenward,et al.  Multiple Imputation and its Application: Carpenter/Multiple Imputation and its Application , 2013 .

[37]  David B. Dunson,et al.  Bayesian data analysis, third edition , 2013 .

[38]  Bradley P Carlin,et al.  Commensurate Priors for Incorporating Historical Information in Clinical Trials Using General and Generalized Linear Models. , 2012, Bayesian analysis.

[39]  Human Medicines Development and Evaluation Concept paper on extrapolation of efficacy and safety in medicine development , 2012 .

[40]  Canary Wharf,et al.  Guidelines on good pharmacovigilance practices (GVP) , 2012 .

[41]  Trudie Lang.  Adaptive Trial Design: Could We Use This Approach to Improve Clinical Trials in the Field of Global Health? , 2011, The American journal of tropical medicine and hygiene.

[42]  P. Austin.  An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies , 2011, Multivariate behavioral research.

[43]  J. Kruschke.  Doing Bayesian Data Analysis: A Tutorial with R and BUGS , 2010 .

[44]  Nancy J Nelson.  Adaptive clinical trial design: has its time come? , 2010, Journal of the National Cancer Institute.

[45]  Elizabeth A Stuart,et al.  Matching methods for causal inference: A review and a look forward. , 2010, Statistical science : a review journal of the Institute of Mathematical Statistics.

[46]  Brian Neelon,et al.  Bayesian Analysis Using Power Priors with Application to Pediatric Quality of Care , 2010 .

[47]  Michael Branson,et al.  A note on the power prior , 2009, Statistics in medicine.

[48]  P. Austin.  Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples , 2009, Statistics in medicine.

[49]  Peter D. Hoff,et al.  A First Course in Bayesian Statistical Methods , 2009 .

[50]  Timothy L. Lash,et al.  Applying Quantitative Bias Analysis to Epidemiologic Data , 2009, Statistics for Biology and Health.

[51]  Cyrus Mehta,et al.  Optimizing Trial Design: Sequential, Adaptive, and Enrichment Strategies , 2009, Circulation.

[52]  Harvey Goldstein,et al.  Modelling measurement errors and category misclassifications in multilevel models , 2008 .

[53]  Gene Pennello,et al.  Experience with Reviewing Bayesian Medical Device Trials , 2007, Journal of biopharmaceutical statistics.

[54]  COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE ( CHMP ) GUIDELINE ON CONDUCT OF PHARMACOVIGILANCE FOR MEDICINES USED BY THE PAEDIATRIC POPULATION , 2007 .

[55]  Keying Ye,et al.  Using power priors to improve the binomial test of water quality , 2006 .

[56]  NOTE FOR GUIDANCE ON CHOICE OF CONTROL GROUP IN CLINICAL TRIALS (CPMP/ICH/364/96) TRANSMISSION TO CPMP , 2006 .

[57]  P. Gustafson.  Measurement Error and Misclassification in Statistics and Epidemiology: Impacts and Bayesian Adjustments , 2003 .

[58]  Peter Congdon.  Bayesian statistical modelling , 2002 .

[59]  D. Pullman,et al.  Adaptive designs, informed consent, and the ethics of research. , 2001, Controlled clinical trials.

[60]  J. Ibrahim,et al.  Power prior distributions for regression models , 2000 .

[61]  S Greenland,et al.  Basic methods for sensitivity analysis of biases. , 1996, International journal of epidemiology.

[62]  R. Carroll,et al.  Measurement error, instrumental variables and corrections for attenuation with applications to meta-analyses. , 1994, Statistics in medicine.

[63]  J M Robins,et al.  Identifiability, exchangeability, and epidemiological confounding. , 1986, International journal of epidemiology.

[64]  S J Pocock,et al.  The combination of randomized and historical controls in clinical trials. , 1976, Journal of chronic diseases.